On November 11, PHARMARON fell 3.06% in Regular Trading, trading at HK$29.14 with turnover of HK$31.13 million.
The clearest catalyst cited for the move was broad weakness across the Life Sciences Tools & Services group rather than a new company-specific negative development.
Recent market updates indicated that PHARMARON had disclosed generally supportive items, including JPMorgan's off-exchange purchase of 771,700 H shares at about HK$26.01 per share, lifting its long position ratio to 17.19%, Morgan Stanley's increase in shares subject to rehypothecation or disposal rights that raised its long position ratio to 6.05%, and a US$10 million commitment by its wholly owned UK subsidiary to HJ Double Helix Fund L.P. Even so, peer pressure dominated on November 11, with WUXI APPTEC down 4.89%, WUXI BIO down 4.31%, GENSCRIPT B-1K down 6.15%, WUXI XDC down 4.24%, and INSILICO down 2.05%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments